Confirmation of anti-HCV EIA reactivities by RIBA and neutralization assay among blood donors and patients with chronic liver disease and hepatocellular carcinoma
The aim of our study was to confirm by Recombinant Immuno-blot Assay (RIBA) and by neutralization assay the repeat positive reactions found by two commercially available EIAs (Ortho and Abbott) when testing samples from volunteer blood donors, patients with chronic liver disease and with hepatocellular carcinoma. Our data show a high confirmatory rate among patients with chronic viral NANBH and HCC, while among donors and patients with CLD other than NANBH the percentage of presumptive EIA positive reactions confirmed by RIBA and/or neutralization assay is much lower. In our experience, the neutralization assay appears to be somewhat more sensitive than RIBA, especially when samples show low EIA optical densities.
KeywordsChronic Liver Disease Primary Biliary Cirrhosis Alcoholic Liver Disease Neutralization Assay Volunteer Blood Donor
Unable to display preview. Download preview PDF.
- 2.Fogarty International Center Proceedings (1976) Nomenclature diagnostic criteria and diagnostic methodology for disease of the liver and biliary tract. Washington D.C.; U.S. Government Printing Office, 22Google Scholar
- 3.Kou G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter HJ, Stevens CE, Tegtmeier GE, Bonino F, Colombo M, Lee WS, Kuo C, Berger K, Shuster JR, Overby LR, Bradley DW, Houghton M (1989) An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244: 363–364Google Scholar